47 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
to support potential approval of any of the Company’s product candidates or those of, or combined with, its collaboration partners; the Company’s goals
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
, global geopolitical tensions, supply chain disruptions, rising interest rates and rising inflation;
our business strategies and goals;
our plans … in the current macroeconomic environment could affect our ability to achieve our goals. We sell our products in countries that face economic volatility
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
performance goals that relate to our key business objectives. Supports our corporate strategy and business plan by linking executive performance to pay.
Target … , that it believes is appropriate to achieve the goals of our executive compensation program and our corporate objectives. However, a significant portion
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
and Israel, global geopolitical tensions, supply chain disruptions, rising interest rates and rising inflation;
our business strategies and goals … and goals;
our plans to collaborate, or statements regarding our current collaborations, and our ability to find future partners and collaborators
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
goals that relate to our key business objectives. Supports our corporate strategy and business plan by linking executive performance to pay.
Target … , that it believes is appropriate to achieve the goals of our executive compensation program and our corporate objectives. However, a significant portion
S-3ASR
t1cp4 8gdb64cy9jx
20 Mar 24
Automatic shelf registration
8:51pm
8-K
EX-99.1
gg2xr 5zh
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
8-K
EX-99.2
oinvw a20rhy
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
EX-10.14
bj9 mu2b1
28 Feb 24
Annual report
7:33am
10-K
jp6jthxgqa ozwcua
28 Feb 24
Annual report
7:33am
10-K
EX-10.12
48p6dj4cs9fs61d o73z
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
yvsk4t1hqo 8nm
28 Feb 24
Annual report
7:33am
8-K
EX-99.2
trjw2 wzf9bgehfi
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.2
dyz3h1hcig
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.1
8xfa4ft0qzji e292xz
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
7qiusnq6r7j
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.4
4vgsywto
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
rwpg0c8kl
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
gg0k4oe03yw
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.3
yvgzadq52gt
20 Jul 22
Securities Purchase Agreement
4:06pm